Fusion Antibodies PLC Notice of AGM (3845X)
28 Agosto 2020 - 8:00AM
UK Regulatory
TIDMFAB
RNS Number : 3845X
Fusion Antibodies PLC
28 August 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Posting of Annual Report and Notice of AGM
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces that its Annual Report
and Accounts for the year ended 31 March 2020, the Notice of Annual
General Meeting ('AGM') and a Form of Proxy will be posted to
shareholders later today and will be available to download from the
Company website shortly.
Details of the AGM
The AGM will be held on 25 September 2020 at 11.00 a.m. at 1
Springbank Road, Springbank Industrial Estate, Belfast, BT17 0QL.
Given the current COVID-19 pandemic and the associated UK
Government measures, it will not be possible to hold an open AGM
and accordingly the AGM this year will be run as a closed meeting.
It will not be possible for shareholders to attend the AGM and the
Company will not be able to grant entry to anyone seeking to attend
the AGM in person.
The AGM will comprise only the formal votes for each resolution
set out in the Notice of AGM. Shareholders are strongly encouraged
to vote via completion of a Form of Proxy, and to appoint the
chairman of the meeting as proxy to ensure votes are counted. The
chairman of the meeting will direct that all resolutions will take
place by way of a poll, rather than on a show of hands. The voting
results of the proposed resolutions will be published on the
Company's website as soon as possible after the conclusion of the
AGM.
Any shareholder wishing to ask questions regarding the business
of the AGM is encouraged to submit their questions to the Board by
email to fusion@walbrookpr.com at least seven days in advance of
the AGM. The Board will consider all questions and, if appropriate,
will provide a written response.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328
5656
James Reeve / Asha Chotai (Corporate Finance)
Tony Quirke (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741
001
Paul McManus Mob: +44 (0)7980 541
893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 100 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster, with the optimal drug candidate and ultimately speed
up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAPRMRTMTBTBBM
(END) Dow Jones Newswires
August 28, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Apr 2023 a Apr 2024